INNATE PHARMA SA Aktie

1,61 EUR +0,08 EUR +5,23 %

09:14:15

STU

1,60 EUR -0,01 EUR -0,37 %

31.12.2025

PAR

INNATE PHARMA SA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.147,67 Mio. EUR

Div. Rendite0,00%

WKNA0LCUJ

ISINFR0010331421

SymbolIPHYF

INNATE PHARMA SA Aktien News

Sortieren:Datum Meistgelesen

16.01.25BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of December 31, 2024

10.01.25Businesswire Innate Pharma Announces Transformative Strategy to Accelerate Growth

20.12.24BusinesswireInnate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

WerbungINNATE PHARMA SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

09.12.24BusinesswireInnate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

06.12.24BusinesswireInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

03.12.24BusinesswireInnate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

20.11.24BusinesswireInnate Pharma Releases Its 2025 Financial Calendar

19.11.24BusinesswireInnate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

13.11.24BusinesswireInnate Pharma Reports Third Quarter 2024 Business Update and Financial Results

08.11.24BusinesswireInnate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

07.11.24BusinesswireInnate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

29.10.24BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conferences

14.10.24BusinesswireInnate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

30.09.24BusinesswireInnate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

23.09.24BusinesswireInnate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors

12.09.24BusinesswireInnate Pharma Reports First Half 2024 Business Update and Financial Results

09.09.24BusinesswireInnate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

05.09.24BusinesswireInnate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update

04.09.24BusinesswireInnate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference

01.08.24BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conference

25.07.24BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of July 10, 2024

18.06.24BusinesswireNumber of Shares and Voting Rights of Innate Pharma as of June 10, 2024

17.06.24BusinesswireInnate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial

04.06.24BusinesswireInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides

28.05.24BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conferences

24.05.24BusinesswireInnate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

23.05.24BusinesswireOutcome of Innate Pharma’s 2024 Annual General Meeting

21.05.24BusinesswireInnate Pharma: Clarification Regarding SAR443579 Designation

15.05.24BusinesswireInnate Pharma Highlights Abstracts Selected for EHA 2024 Congress

14.05.24BusinesswireInnate Pharma Reports First Quarter 2024 Business Update and Financial Results

07.05.24BusinesswireInnate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

15.04.24BusinesswireInnate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

15.04.24BusinesswireInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

10.04.24BusinesswireInnate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

09.04.24BusinesswireInnate Pharma Announces Its Participation in Upcoming Investor Conference

05.04.24BusinesswireInnate Pharma Files Its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F

21.03.24BusinesswireInnate Pharma Reports Full Year 2023 Financial Results and Business Update

19.03.24BusinesswireInnate Pharma Announces Its Participation to Upcoming Investor Conference

14.03.24BusinesswireInnate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

06.03.24BusinesswireInnate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

INNATE PHARMA SA News

INNATE PHARMA SA News: auf dieser Seite finden Sie alle INNATE PHARMA SA News und Nachrichten zur INNATE PHARMA SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch INNATE PHARMA SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um INNATE PHARMA SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.